Core Viewpoint - The article discusses the strategic investment by Zhong Shanshan, who will hold 10.58% of Jinbo Biological after a recent share transfer and subscription agreement, marking a significant development for the company and the North Exchange market [2][5]. Group 1: Share Transfer and Investment Details - On June 26, Jinbo Biological announced that its controlling shareholder, Yang Xia, signed a share transfer agreement with Hangzhou Jiushi, transferring 5% of the company's total shares at a price of 243.84 RMB per share, totaling 1.403 billion RMB [3][4]. - Jinbo Biological will issue shares equivalent to 6.24% of its total shares to Yang Xia's strategic investor, Yangsheng Tang, with a financing amount not exceeding 2 billion RMB [3][4]. Group 2: Ownership Structure Post-Transaction - After the equity change, Yang Xia will hold 50.73% of Jinbo Biological, while Hangzhou Jiushi and Yangsheng Tang will hold 4.71% and 5.87% respectively [4][5]. - Yangsheng Tang, controlled by Zhong Shanshan, also holds significant stakes in other companies, including 66.88% of Nongfu Spring and 55.79% of Wantai Biological [4]. Group 3: Strategic Focus and Future Plans - The core focus of the fundraising is the development of a humanized collagen FAST database and product development platform, which aims to enhance Jinbo Biological's product offerings in various medical fields [7]. - The integration of AI design parameters with industrial production processes is expected to accelerate the transformation of research outcomes into market-ready products, creating a "data + algorithm" competitive advantage [7]. - The collaboration with Yangsheng Tang is anticipated to leverage both companies' strengths, enhancing market capabilities and accelerating technological development [7].